Diagnosis, Risk Stratification, And Management Of Pulmonary Hypertension Of Sickle Cell Disease.

Publication Date: March 5, 2014

Key Points

Key Points

Pulmonary hypertension (PH) and right heart failure are well-established risk factors for mortality in sickle cell disease (SCD).

Observational studies have consistently shown that increased tricuspid regurgitant jet velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro–brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension measured by right heart catheterization are all independent risk factors for mortality in adults.

To reduce the variability and to improve the quality of care that patients with SCD receive, the ATS developed clinical practice guidelines to advise hematologists, pulmonologists, cardiologists, pediatricians, and internists about how to identify and manage patients with SCD who are at increased risk for mortality.

Diagnosis

...iagnosi...

...atification guides clinical decision...


...creased risk for mortality is defined as a TR...


...Sample Questions for Evaluation of...


...osed Algorithm for Evaluation of P...


...rdiogram of a Patient with Pulmonary Hypertension...


Treatment

...eatment...

...nts with SCD who have an increased risk for...


...atients with SCD who have an increased risk f...


...or patients with SCD who have RHC-co...


...patients with SCD who have elevated TRV alone or...


...ients with SCD who have RHC-confirmed PH, the ATS...


...ents with SCD who have RHC-confirme...


...with SCD who have RHC-confirmed marked elevation...


...e 2. MedicationsHaving trouble view...